公开(公告)号：US20180111988A1

公开(公告)日：2018-04-26

申请号：US15791674

申请日：2017-10-24

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Nobuyuki Yasuda ,  Fumitoshi Tago ,  Hiroko Baba ,  Tomohisa Nakano ,  Masahiko Mori

IPC: C07K16/24 ,  A61P19/02

CPC classification number: C07K16/24 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61P19/02 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/90 ,  C07K2317/94

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an anti-fractalkine antibody, and a method for treating rheumatoid arthritis using the pharmaceutical composition, wherein the pharmaceutical composition and the method bring about therapeutically effective amelioration in rheumatoid arthritis after administration to a human subject. The present invention provides a pharmaceutical composition for the treatment of rheumatoid arthritis. The pharmaceutical composition in a method for treating rheumatoid arthritis comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient and is used such that at least 100 mg per dose of the anti-fractalkine antibody is subcutaneously administered to a human in need thereof.

公开(公告)号：US20220205980A1

公开(公告)日：2022-06-30

申请号：US17601908

申请日：2020-04-20

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Nobuyuki Yasuda ,  Tomohiro Yamada ,  Fumitoshi Tago ,  Seiichiro Hojo ,  Toshio Imai

IPC: G01N33/50 ,  C07K16/24 ,  A61P19/02

Abstract: An object of the present invention is to provide a method for predicting a therapeutic effect of a drug that inhibits FKN-CX3CR1 interaction on rheumatoid arthritis in a rheumatoid arthritis subject, and novel and more effective therapeutic agent for rheumatoid arthritis exploiting the method. In order to predict a therapeutic effect of a drug that inhibits fractalkine (FKN)-CX3CR1 interaction in a rheumatoid arthritis subject, provided is a method comprising predicting the therapeutic effect of the drug in the subject on the basis of a measurement value of CD16+ monocytes in a biological sample obtained from the subject before the start of administration of the drug.